5American Thoracic Society,Infentious Diseases Society of America.Guidelines for the management of adultswith hospit-alacquired,ventilator-associated,and healthcare-associated pneumonia.Am J Respir Crit Care Med,2005,171:388-416.
6Hoban DJ,Doern GV,Fluit AC,et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae,Haemophilus influenzae and Moraxella catarrhalis in the Sentry antimicrobial surveillance program 1997-99. Clin Infect Dis,2001 ;32:81 ～ 93
8Takemura H,Terakubo S,Yamamoto H, et al. Susceptibilities of Fluoroquinolone-Resistant Haemophilus parainfluenzae Isolates from Japanese Patients with Respiratory Infections to Five Fluoroquinolones and Other Antimicrobial Agents. Antimicrob Agents Chemother, 2003 ;47: 3996 ～ 3997
9Mitchell JL, Hill SI. Immune response to Haemophilus parainfluenzae in patients with chronic obstructive lung disease. Clin Diagn Lab Immunol,2000;7:25 ～30
10Pillai,A, Mitchell JL, Hill SL, et al. A case of Haemophilus parainfluenzae pneumonia. Thorax, 2000; 55: 623 ～ 624
7American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Grit Care Med, 2005, 171..388-416.
8Sundar, K.M., Nielsen, D., Sperry, P, et aI.Comparison of ventilator-associated pneumonia (VAP) rates between different ICUs: Implications of a zero VAP rate[J]. Journal of critical care, 2012, 27 (1) : 26-32.
